Advertisement
COR vs MCK
Which Stock Would AI Choose? Cencora (COR) vs. McKesson (MCK) Stock Comparison
Key Takeaways
- COR (Cencora) and MCK (McKesson) are two of the three dominant U.S. pharmaceutical wholesale distributors, giving both durable scale and defensive cash-flow characteristics.
- MCK carries the stronger recent momentum, trading near its 52-week high with a roughly 22% year-to-date advance, while COR has cooled after pulling back from its own record level.
- COR is leaning into specialty and oncology services through its up-to-$2.4 billion American Oncology Network deal, while MCK has locked in visibility by renewing its CVS distribution agreement through 2032.
- Tickeron AI Verdict: MCK is the preferred ticker, reflecting stronger trend consistency, relative strength, and clearer near-term catalysts.
- For more detail, explore COR Major News and COR Today's Price Move, as well as MCK Major News and MCK Today's Price Move.
- To see how AI-driven strategies are navigating this market, explore Trending AI Robots.
Introduction
Investors evaluating defensive healthcare exposure often weigh the two largest publicly traded U.S. pharmaceutical distributors. Cencora (COR) and McKesson (MCK) both sit at the center of the drug supply chain, generating massive revenue with relatively thin margins and a steady, largely non-cyclical demand profile. This stock comparison is relevant for long-term investors seeking stability and for traders gauging relative momentum between two sector peers. Although the companies share a core business model, their growth strategies, recent price behavior, and market positioning have diverged, making a head-to-head assessment useful for understanding which name currently carries the stronger trend and catalyst profile.
COR Overview and Recent Performance
Cencora (COR), formerly AmerisourceBergen, is one of the "big three" U.S. pharmaceutical wholesalers, distributing branded, generic, and specialty drugs to pharmacies, hospitals, and providers. The company also operates global specialty logistics through World Courier and animal health distribution via MWI Animal Health, with annual revenue exceeding $300 billion.
In recent weeks, COR has focused on expanding its higher-margin specialty footprint, agreeing to acquire American Oncology Network in a deal valued at up to $2.4 billion. This builds on existing platforms such as OneOncology and Retina Consultants of America. Recent market activity, however, has been mixed: the stock has pulled back roughly 14% from its 52-week high, and near-term momentum has cooled even as three-month and multi-year returns remain strong. Quarterly revenue missed estimates while adjusted earnings per share (EPS, or profit divided by shares outstanding) topped forecasts, and management raised its fiscal 2026 EPS outlook while authorizing a fresh $2 billion buyback program.
MCK Overview and Recent Performance
McKesson (MCK) is the largest U.S. pharmaceutical distributor, reporting roughly $403 billion in fiscal 2026 revenue. Its business spans four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. This diversified structure positions it across distribution, community oncology, and technology-enabled access services.
Recent market activity has favored MCK, which trades near its 52-week high after a strong multi-month advance. Sentiment has been supported by the renewal of its CVS distribution partnership through June 2032, a $741.5 million Defense Logistics Agency contract, and continued oncology-platform growth. Fiscal 2026 adjusted EPS rose 18.3%, and management issued fiscal 2027 adjusted EPS guidance of $43.80 to $44.60 while reaffirming long-term EPS growth targets of 13% to 16%. Analysts have responded with a wave of price-target increases, and the stock's relative strength rating has moved into leading territory.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's strongest-performing automated strategies. Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, each configured with its own trading style, strategy, timeframe, risk profile, and performance statistics. Because market conditions shift, not every bot suits every environment, so only those best aligned with the current tape earn a place in the curated Trending section. Whether a trader favors short-term momentum or longer-horizon trend following, this page offers a streamlined way to review currently relevant strategies. Investors comparing names like COR and MCK may find value in exploring Trending AI Robots to see how automated systems are currently positioned.
Head-to-Head Comparison
The two companies differ most in scale, growth strategy, and momentum. MCK is roughly twice Cencora's market capitalization and has leaned heavily into oncology and data-driven biopharma services, reinforced by acquisitions and technology investments. COR is also expanding specialty and oncology services but remains more concentrated in core wholesale distribution and international specialty logistics.
On valuation, COR trades at a lower price-to-earnings (P/E) multiple, while MCK commands a premium consistent with its stronger recent growth and higher market leadership. Momentum diverges sharply: MCK is pressing its highs with positive year-to-date performance, whereas COR is consolidating below its peak. Risk factors are similar and include drug-pricing regulation, customer concentration, and cyber-related vulnerabilities, but MCK's renewed CVS contract reduces a key customer-retention risk in the near term.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor MCK over COR in the current environment. The MCK trend appears more consistent, with the stock sustaining a position near its 52-week high, demonstrating relative strength, and benefiting from multiple near-term catalysts including contract renewals and reaffirmed long-term growth targets. While COR offers an arguably lower valuation and a credible specialty-services growth story, its recent momentum has cooled, which tends to weigh against it in trend-based scoring. This reflects a probabilistic, momentum-oriented assessment rather than a definitive forecast of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COR is a Hold and MCK is a Hold.
COR in upward trend: 10-day moving average crossed above 50-day moving average on October 14, 2026
The 10-day moving average for COR crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 26 of 43 cases where COR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.
COR moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for COR moved above the 200-day moving average on October 01, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +2.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where COR advanced for three days, in 235 of 384 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
Bearish Trend Analysis
The 10-day RSI Indicator for COR moved out of overbought territory on October 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 49 similar instances where the indicator moved out of overbought territory. In 23 of the 49 cases, the stock moved lower in the following days. This puts the odds of a move lower at 47%.
The Momentum Indicator moved below the 0 level on October 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on COR as a result. In 37 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 44%.
The Moving Average Convergence Divergence Histogram (MACD) for COR turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 27 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
COR broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for COR entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 13 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 21 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. COR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.131) is normal, around the industry mean (12.613). P/E Ratio (24.970) is within average values for comparable stocks, (10.633). Projected Growth (PEG Ratio) (0.636) is also within normal values, averaging (2.016). Dividend Yield (0.007) settles around the average of (0.138) among similar stocks. P/S Ratio (0.187) is also within normal values, averaging (4.260).
MCK sees its Stochastic Oscillator recovers from oversold territory
On October 30, 2026, the Stochastic Oscillator for MCK moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 48 instances where the indicator left the oversold zone. In 37 of the 48 cases the stock moved higher in the following days. This puts the odds of a move higher at over 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
MCK moved above its 50-day moving average on October 01, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MCK crossed bullishly above the 50-day moving average on October 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.
Following a +1.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where MCK advanced for three days, in 251 of 379 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 258 of 355 cases where MCK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for MCK moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 54 similar instances where the indicator moved out of overbought territory. In 23 of the 54 cases, the stock moved lower in the following days. This puts the odds of a move lower at 43%.
The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MCK as a result. In 41 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 42%.
The Moving Average Convergence Divergence Histogram (MACD) for MCK turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 25 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 48%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
MCK broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-27.453) is normal, around the industry mean (12.613). MCK has a moderately high P/E Ratio (26.666) as compared to the industry average of (10.633). Projected Growth (PEG Ratio) (1.616) is also within normal values, averaging (2.016). Dividend Yield (0.004) settles around the average of (0.138) among similar stocks. P/S Ratio (0.265) is also within normal values, averaging (4.260).
The Tickeron Price Growth Rating for this company is 16 (best 1 - 100 worst), indicating outstanding price growth. MCK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
COR | MCK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 86 | 93 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 21 | 8 | |
SMR RATING 1..100 | 13 | 100 | |
PRICE GROWTH RATING 1..100 | 45 | 16 | |
P/E GROWTH RATING 1..100 | 79 | 71 | |
SEASONALITY SCORE 1..100 | 50 | 48 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MCK's Valuation (13) in the Medical Distributors industry is significantly better than the same rating for COR (80) in the Real Estate Investment Trusts industry. This means that MCK’s stock grew significantly faster than COR’s over the last 12 months.
MCK's Profit vs Risk Rating (8) in the Medical Distributors industry is in the same range as COR (21) in the Real Estate Investment Trusts industry. This means that MCK’s stock grew similarly to COR’s over the last 12 months.
COR's SMR Rating (13) in the Real Estate Investment Trusts industry is significantly better than the same rating for MCK (100) in the Medical Distributors industry. This means that COR’s stock grew significantly faster than MCK’s over the last 12 months.
MCK's Price Growth Rating (16) in the Medical Distributors industry is in the same range as COR (45) in the Real Estate Investment Trusts industry. This means that MCK’s stock grew similarly to COR’s over the last 12 months.
MCK's P/E Growth Rating (71) in the Medical Distributors industry is in the same range as COR (79) in the Real Estate Investment Trusts industry. This means that MCK’s stock grew similarly to COR’s over the last 12 months.
| COR | MCK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 47% | 2 days ago 43% |
| Stochastic ODDS (%) | 2 days ago 60% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 44% | 2 days ago 42% |
| MACD ODDS (%) | 2 days ago 50% | 2 days ago 48% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 66% |
| TrendMonth ODDS (%) | 2 days ago 66% | 2 days ago 70% |
| Advances ODDS (%) | 2 days ago 61% | 2 days ago 66% |
| Declines ODDS (%) | 7 days ago 43% | 7 days ago 42% |
| BollingerBands ODDS (%) | 2 days ago 57% | 2 days ago 38% |
| Aroon ODDS (%) | 2 days ago 43% | 2 days ago 73% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COR’s FA Score shows that 2 FA rating(s) are green while MCK’s FA Score has 3 green FA rating(s).
- COR’s FA Score: 2 green, 3 red.
- MCK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COR’s TA Score shows that 5 TA indicator(s) are bullish while MCK’s TA Score has 5 bullish TA indicator(s).
- COR’s TA Score: 5 bullish, 6 bearish.
- MCK’s TA Score: 5 bullish, 5 bearish.
Price Growth
COR (@Medical Distributors) experienced а +2.38% price change this week, while MCK (@Medical Distributors) price change was +0.55% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was +4.46%. For the same industry, the average monthly price growth was -9.12%, and the average quarterly price growth was -19.66%.
Reported Earning Dates
COR is expected to report earnings on Nov 04, 2026.
MCK is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Medical Distributors (+4.46% weekly)Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
Advertisement